Long noncoding RNA FEZF1-AS1 in human cancers
Copyright © 2019 Elsevier B.V. All rights reserved..
Long noncoding RNAs (lncRNAs) have been shown to play key roles in various human tumors. Ectopic expression of the lncRNA FEZ finger zinc 1 antisense 1 (FEZF1-AS1) have been reported in different cancers, including colorectal cancer, gastric neoplasia, hepatocellular carcinoma and so on. Summarizing all literature correlated with FEZF1-AS1, it is obvious that FEZF1-AS1 is mainly involved in tumorigenesis and progression through competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA) and recruiting mechanism. Moreover, the aberrant expression of FEZF1-AS1 is related to clinical features of patients with cancers, and regulates cellular proliferation, anti-apoptosis, invasion and metastasis through diverse underlying mechanisms. The role of FEZF1-AS1 in carcinogenesis and progression suggests that it may be a potential diagnostic biomarker or a novel therapeutic target for cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:497 |
|---|---|
| Enthalten in: |
Clinica chimica acta; international journal of clinical chemistry - 497(2019) vom: 31. Okt., Seite 20-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Yuanshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 11.02.2020 Date Revised 11.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cca.2019.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298901021 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298901021 | ||
| 003 | DE-627 | ||
| 005 | 20231225095155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cca.2019.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM298901021 | ||
| 035 | |a (NLM)31276636 | ||
| 035 | |a (PII)S0009-8981(19)31941-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Yuanshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long noncoding RNA FEZF1-AS1 in human cancers |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2020 | ||
| 500 | |a Date Revised 11.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier B.V. All rights reserved. | ||
| 520 | |a Long noncoding RNAs (lncRNAs) have been shown to play key roles in various human tumors. Ectopic expression of the lncRNA FEZ finger zinc 1 antisense 1 (FEZF1-AS1) have been reported in different cancers, including colorectal cancer, gastric neoplasia, hepatocellular carcinoma and so on. Summarizing all literature correlated with FEZF1-AS1, it is obvious that FEZF1-AS1 is mainly involved in tumorigenesis and progression through competing endogenous RNA (ceRNA) which sponges tumor-suppressive microRNA (miRNA) and recruiting mechanism. Moreover, the aberrant expression of FEZF1-AS1 is related to clinical features of patients with cancers, and regulates cellular proliferation, anti-apoptosis, invasion and metastasis through diverse underlying mechanisms. The role of FEZF1-AS1 in carcinogenesis and progression suggests that it may be a potential diagnostic biomarker or a novel therapeutic target for cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a FEZF1-AS1 | |
| 650 | 4 | |a Long noncoding RNA | |
| 650 | 7 | |a FEZF1 protein, human |2 NLM | |
| 650 | 7 | |a RNA, Antisense |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a Repressor Proteins |2 NLM | |
| 700 | 1 | |a Xu, Shuwan |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Haoming |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Zewei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Rongju |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Enyu |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Xingming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinica chimica acta; international journal of clinical chemistry |d 1956 |g 497(2019) vom: 31. Okt., Seite 20-26 |w (DE-627)NLM000002054 |x 1873-3492 |7 nnns |
| 773 | 1 | 8 | |g volume:497 |g year:2019 |g day:31 |g month:10 |g pages:20-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cca.2019.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 497 |j 2019 |b 31 |c 10 |h 20-26 | ||